Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–2515

@inproceedings{Schernthaner2013CanagliflozinCW,
  title={Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508–2515},
  author={Guntram Schernthaner and J. M. Gross and John Rosenstock and Michael Guarisco and Min Fu and Jacqueline Yee and Masato Kawaguchi and William Canovatchel and Gary Meininger},
  booktitle={Diabetes care},
  year={2013}
}
OBJECTIVE To evaluate the efficacy and safety of canagliflozin, a sodium glucose cotransporter 2 inhibitor, compared with sitagliptin in subjects with type 2 diabetes inadequately controlled with metformin plus sulfonylurea. RESEARCH DESIGN AND METHODS In this 52-week, randomized, double-blind, active-controlled, phase 3 study, subjects using stable metformin plus sulfonylurea (N = 755) received canagliflozin 300 mg or sitagliptin 100 mg daily. Primary end point was change from baseline in… CONTINUE READING
Highly Influential
This paper has highly influenced 20 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
137 Citations
38 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 137 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

fi cacy and safety of canagli fl ozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

  • K Stenlöf, WT Cefalu, Kim K-A
  • Diabetes Obes Metab
  • 2013

Canagli fl ozinDIA 2001 StudyGroup . Doseranging effects of canagli fl ozin , a sodiumglucose cotransporter 2 inhibitor , as add - on to metformin in subjects with type 2 diabetes

  • J Rosenstock, N Aggarwal, D Polidori
  • Diabetes Care
  • 2012

Canagliflozin, a sodium glucose cotransporter 2 inhibitor, reduces bodyweight mainly through loss of fat mass in subjects with type 2 diabetes

  • S Toubro, WT Cefalu, J Xie
  • Diabetologia
  • 2012
1 Excerpt

Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with glimepiride in patients with type 2 diabetes on background metformin

  • L Niskanen, WT Cefalu, LA Leiter
  • Diabetologia 2012;55(Suppl
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…